INHIBITION OF THE BINDING OF HUMAN IGE TO ITS RECEPTOR BY TETRACYCLIC COMPOUNDS FOR THE ALLEVIATION OF IGE-MEDIATED IMMUNE RESPONSE

摘要

Disclosed are chemical agents with unexpected activity to inhibit the interactions between human immunoglobulin E (IgE) and its receptor (Fc epsilon RI) which interactions are known to be involved in triggering allergic responses. The agents may be used to modulate the allergic response in the treatment of various clinical conditions, including rhinitis, asthma, urticaria, atopic dermatitis, and anaphylactic shock. The agents can be formulated for oral, topical or parenteral administration.